Pharmaceuticals News

– Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) –– Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 –– Updating 2026 Full Year...

Teva and Samsung Bioepis agree to commercialize two FDA-approved immunology biosimilars in the U.S., expanding Teva’s biosimilars portfolio

Company announcement no. 44 - 2603 November 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

AGC Biologics delivers flexible, dual-site CDMO services for commercial biologics, combining Copenhagen and Yokohama manufacturing for resilient supply.

TME Pharma welcomes this independent external validation of its therapeutic approach in glioblastoma by the German medical community

TME Pharma se réjouit de cette validation externe indépendante de son approche thérapeutique du glioblastome par la communauté médicale allemande

The Novo Nordisk Foundation is awarding up to DKK 100 million (EUR 13.3 million) over four years to establish AI4GRIDS, a Nordic research initiative

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 03, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to...

Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 03. November 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,...

Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO (aprocitentan).